Does the media prefer RVMD or MDGL?

In the previous week, Revolution Medicines had 12 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 14 mentions for Revolution Medicines and 2 mentions for Madrigal Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.57 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDGL or ALNY?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BIIB or MDGL?

In the previous week, Biogen had 7 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 9 mentions for Biogen and 2 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.02 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDGL or ROIV?

In the previous week, Roivant Sciences had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 3 mentions for Roivant Sciences and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Roivant Sciences' score of -0.54 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer INSM or MDGL?

In the previous week, Insmed had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 4 mentions for Insmed and 2 mentions for Madrigal Pharmaceuticals. Insmed's average media sentiment score of 0.59 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Madrigal Pharmaceuticals (MDGL) Competitors

$499.40 -0.31 (-0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$499.49 +0.09 (+0.02%)

As of 04:18 PM Eastern

Compare

MDGL vs. RVMD, ALNY, BIIB, ROIV, and INSM

Should you buy Madrigal Pharmaceuticals stock or one of its competitors? Madrigal Pharmaceuticals's main competitors and comparable companies include Revolution Medicines (RVMD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Madrigal Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,826.30	-$1.13B	-$8.82	N/A
Madrigal Pharmaceuticals	$958.40M	11.95	-$288.28M	-$12.89	N/A

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

In the previous week, Revolution Medicines had 12 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 14 mentions for Revolution Medicines and 2 mentions for Madrigal Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.57 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines presently has a consensus target price of $234.33, suggesting a potential upside of 13.36%. Madrigal Pharmaceuticals has a consensus target price of $710.20, suggesting a potential upside of 43.25%. Given Madrigal Pharmaceuticals' higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Revolution Medicines beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Alnylam Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.95	-$288.28M	-$12.89	N/A
Alnylam Pharmaceuticals	$3.71B	8.03	$313.75M	$5.38	41.41

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Madrigal Pharmaceuticals currently has a consensus target price of $710.20, suggesting a potential upside of 43.25%. Alnylam Pharmaceuticals has a consensus target price of $366.90, suggesting a potential upside of 64.68%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Madrigal Pharmaceuticals has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Madrigal Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Biogen had 7 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 9 mentions for Biogen and 2 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.02 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.30	$1.29B	$5.65	39.05
Madrigal Pharmaceuticals	$958.40M	11.95	-$288.28M	-$12.89	N/A

Biogen currently has a consensus price target of $230.14, indicating a potential upside of 4.30%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 43.25%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Biogen has a net margin of 8.32% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Biogen's return on equity of 11.18% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Biogen has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market.

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Roivant Sciences?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Madrigal Pharmaceuticals presently has a consensus price target of $710.20, suggesting a potential upside of 43.25%. Roivant Sciences has a consensus price target of $45.64, suggesting a potential upside of 27.82%. Given Madrigal Pharmaceuticals' higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Roivant Sciences had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 3 mentions for Roivant Sciences and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Roivant Sciences' score of -0.54 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Madrigal Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.95	-$288.28M	-$12.89	N/A
Roivant Sciences	$8.26M	3,122.33	-$299.77M	-$0.53	N/A

Summary

Madrigal Pharmaceuticals beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Madrigal Pharmaceuticals has higher revenue and earnings than Insmed. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.16	-$1.28B	-$4.11	N/A
Madrigal Pharmaceuticals	$958.40M	11.95	-$288.28M	-$12.89	N/A

Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

In the previous week, Insmed had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 4 mentions for Insmed and 2 mentions for Madrigal Pharmaceuticals. Insmed's average media sentiment score of 0.59 beat Madrigal Pharmaceuticals' score of 0.57 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed presently has a consensus price target of $200.57, suggesting a potential upside of 84.43%. Madrigal Pharmaceuticals has a consensus price target of $710.20, suggesting a potential upside of 43.25%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Insmed's net margin of -76.94%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Insmed beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDGL vs. The Competition

Export

Metric	Madrigal Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.54B	$3.84B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-38.74	13.44	274.42	26.03
Price / Sales	12.04	1,285.38	600.72	89.51
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	18.82	16.64	10.92	6.32
Net Income	-$288.28M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-3.32%	-2.99%	-2.07%	-1.66%
1 Month Performance	-8.69%	-10.68%	-6.32%	-3.93%
1 Year Performance	11.07%	21.44%	8.92%	2.82%

Madrigal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDGL Madrigal Pharmaceuticals	3.0237 of 5 stars	$499.40 -0.1%	$710.20 +42.2%	+11.3%	$11.54B	$958.40M	N/A	915
RVMD Revolution Medicines	3.0542 of 5 stars	$201.74 -1.6%	$234.33 +16.2%	+349.0%	$43.93B	$11.58M	N/A	883	Insider Trade Analyst Revision
ALNY Alnylam Pharmaceuticals	3.9167 of 5 stars	$255.36 -0.2%	$367.20 +43.8%	-49.8%	$34.25B	$3.71B	47.46	2,770	Analyst Forecast
BIIB Biogen	3.0438 of 5 stars	$228.69 +0.5%	$230.14 +0.6%	+44.5%	$33.63B	$9.89B	40.48	7,500	Trending News
ROIV Roivant Sciences	2.6295 of 5 stars	$36.98 +3.3%	$45.64 +23.4%	+125.4%	$25.86B	$8.26M	N/A	721

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDGL) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Summary

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Summary

How does Madrigal Pharmaceuticals compare to Roivant Sciences?

Summary

How does Madrigal Pharmaceuticals compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Madrigal Pharmaceuticals compare to Revolution Medicines?

Which has stronger valuation & earnings, RVMD or MDGL?

Which has more volatility & risk, RVMD or MDGL?

Do insiders & institutionals hold more shares of RVMD or MDGL?

Is RVMD or MDGL more profitable?

Does the media prefer RVMD or MDGL?

Do analysts rate RVMD or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Which has better earnings and valuation, MDGL or ALNY?

Does the media prefer MDGL or ALNY?

Is MDGL or ALNY more profitable?

Do analysts recommend MDGL or ALNY?

Do institutionals and insiders hold more shares of MDGL or ALNY?

Which has more volatility & risk, MDGL or ALNY?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Does the media refer more to BIIB or MDGL?

Do institutionals and insiders believe in BIIB or MDGL?

Which has stronger valuation and earnings, BIIB or MDGL?

Do analysts rate BIIB or MDGL?

Is BIIB or MDGL more profitable?

Which has more volatility and risk, BIIB or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Roivant Sciences?

Is MDGL or ROIV more profitable?

Do analysts prefer MDGL or ROIV?

Does the media prefer MDGL or ROIV?

Which has more risk and volatility, MDGL or ROIV?

Do insiders and institutionals hold more shares of MDGL or ROIV?

Which has better earnings and valuation, MDGL or ROIV?

Summary

How does Madrigal Pharmaceuticals compare to Insmed?

Which has preferable valuation & earnings, INSM or MDGL?

Which has more risk & volatility, INSM or MDGL?

Does the media prefer INSM or MDGL?

Do analysts recommend INSM or MDGL?

Is INSM or MDGL more profitable?

Do insiders and institutionals hold more shares of INSM or MDGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools